痛风伴高尿酸血症应用非布司他治疗效果及其对QOL评分的影响

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (511 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of non-budastatin therapy on the quality of life (QOL) of gout patients with hyperuricemia.Methods One hundred and ten patients with gout and hyperuricemia treated in our hospital were randomly selected for a comparative investigation. Half of these patients were treated with allopurinol and served as the control group, and the rest were treated with febuxostat as the observation group.Results All the patients in the observation group were treated effectively and the total effective rate was 100.00%. The therapeutic effect was poor in six cases in the control group, with a total effective rate of 89.09%. There was no significant difference in uric acid levels between the two groups before treatment. After treatment, the average level of uric acid in the observation group was (352.26±5.47)μmol/L, significantly lower than (368.25±5.46)μmol/L in the control group. Only one patient in the observation group had nausea during treatment, and the incidence of adverse reactions was 1.82%. In the control group, 8 patients had elevated transaminase, abnormal liver function and nausea during treatment, and the incidence of adverse reactions was 14.55%. The proportion of patients with good QOL scores in the observation group was significantly higher than that in the control group.Conclusions Feibusta is superior to allopurinol in the treatment of gout with hyperuricemia and helps to improve the quality of life of patients.

Key words： gout hyperuricemia febuxostat

Received: 10 July 2018

ZTFLH:

R589.7

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SUN Changyou
	LIU Qing
	LI Qing
	SU Chang
	LI Kai
	WANG Yun

Cite this article:

SUN Changyou,LIU Qing,LI Qing等. Therapeutic effect of febuxostat in patients with gout and hyperuricemia and its influence on QOL scores[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2018, 29(11): 1021-1023.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2018/V29/I11/1021

[1]	陶小军,金星,陶沙,等.不同剂量非布司他对痛风伴高尿酸血症的效果及对内皮素-1水平的影响[J]. 中国全科医学,2014,17(2): 170-172.
[2]	沈赟,金星,陶沙,等.不同剂量非布司他与别嘌呤醇对高尿酸血症伴痛风患者可溶性细胞间黏附分子1影响的对比观察[J]. 中国全科医学,2014,17(14): 1665-1667.
[3]	黄金沐,池慧琼,林少凯.比较非布司他片与别嘌呤醇片治疗高尿酸血症伴痛风的临床研究[J]. 中国临床药理学杂志,2017,33(20): 2009-2012.
[4]	张文化,钱先. 基于德尔菲法的痛风危险因素研究[J]. 中医药导报, 2017, 23(4): 47-50.
[5]	舒涛,蒋中才,高代丽. 不同剂量非布司他对痛风伴高尿酸血症患者血尿酸水平及血清ET-1、NO和MPO的影响[J]. 解放军医药杂志,2017,29(4):106-108.
[6]	赵艳红.非布司他和别嘌呤醇治疗原发性痛风疗效和安全性的比较[J].浙江医学,2018,6(10): 58-61.
[7]	Lei Y P. Analysis of effect of dieting intervention in treatment of senile patients with type 2 diabetes and arthrolithiasis [J]. Systems Med, 2017, 6(2): 47-50.
[8]	申筠,薄艳.非布司他治疗痛风及高尿酸血症临床研究及应用进展[J].中国地方病防治杂志,2016,9(10): 1107-1108.
[9]	张文,解为慈,徐金娥,等.非布司他对痛风合并高尿酸血症患者血清sICAM-1,ET-1及尿酸水平的影响[J]. 现代生物医学进展,2016,16(27): 5303-5305.
[10]	郭丽环,苏伟海,勾威,等.非布司他与别嘌醇治疗痛风高尿酸血症临床观察[J].中国煤炭工业医学杂志,2018,1(2): 47-51.
[11]	周玥,陈建军,楼季庄,等.非布司他治疗痛风伴重度肾功能不全患者的疗效[J]. 江苏医药,2016,42(18): 2038-2040.
[12]	隋磊,杨蕊菲,杜健,等. 非布司他联合手术治疗痛风结节的疗效观察[J].中国现代医学杂志,2015,25(29): 73-77.
[13]	丘余良,李述捷,阮诗玮. 非布司他对高尿酸血症患者临床应用的Meta分析[J].中国中西医结合肾病杂志,2016,17(6): 511-516.

[1]	. [J]. Med. J. Chin. Peop. Armed Poli. Forc., 2018, 29(3): 217-220.